Provided is a method of producing a solid dispersion that can improve solubility of a hardly soluble polyphenol in water. Specifically, provided is a method of producing a solid dispersion containing an amorphous hardly soluble polyphenol, the method including the steps of: mixing (A) a hardly soluble polyphenol, (B) at least one selected from the group consisting of a plant-derived polysaccharide, a seaweed-derived polysaccharide, and a microorganism-derived polysaccharide, a plant-derived polypeptide, and a microorganism-derived polypeptide, and (C) at least one selected from the group consisting of a monosaccharide and a disaccharide, followed by melting of the mixture by heating; and solidifying the molten product by cooling.

Provided is a method of producing a solid dispersion that can improve solubility of a hardly soluble polyphenol in water. Specifically, provided is a method of producing a solid dispersion containing an amorphous hardly soluble polyphenol, the method including the steps of: mixing (A) a hardly soluble polyphenol, (B) at least one selected from the group consisting of a plant-derived polysaccharide, a seaweed-derived polysaccharide, and a microorganism-derived polysaccharide, a plant-derived polypeptide, and a microorganism-derived polypeptide, and (C) at least one selected from the group consisting of a monosaccharide and a disaccharide, followed by melting of the mixture by heating; and solidifying the molten product by cooling.

Administration of certain chromium complexes in combination with a starch provide unexpected benefits regarding increasing amino acid absorption, protein synthesis, exercise tolerance, lean muscle mass, skeletal muscle hypertrophy, muscle power, muscle endurance, muscle strength, FSR, and decreasing delayed onset muscle soreness, muscle protein breakdown, and fat mass.

Administration of certain chromium complexes in combination with a starch provide unexpected benefits regarding increasing amino acid absorption, protein synthesis, exercise tolerance, lean muscle mass, skeletal muscle hypertrophy, muscle power, muscle endurance, muscle strength, FSR, and decreasing delayed onset muscle soreness, muscle protein breakdown, and fat mass.

The present disclosure relates to polygalacturonan rhamnogalacturonan (PGRG1) compositions, as well as methods of making and methods of using said compositions in medicinally useful and pharmaceutically useful forms. Specifically, the present disclosure provides purified PGRG1 compositions isolated from roots of the Astragalus genus of plants, and more particularly from the species Astragalus membranaceus, as well as PGRG1 compositions having a weight average molecular weight of at least 40 kiloDaltons (kDa).

The present disclosure relates to polygalacturonan rhamnogalacturonan (PGRG1) compositions, as well as methods of making and methods of using said compositions in medicinally useful and pharmaceutically useful forms. Specifically, the present disclosure provides purified PGRG1 compositions isolated from roots of the Astragalus genus of plants, and more particularly from the species Astragalus membranaceus, as well as PGRG1 compositions having a weight average molecular weight of at least 40 kiloDaltons (kDa).

Aspects of the invention provide methods for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases.

The invention relates to a method for the preparation of dry formulations of dairy probiotic bacteria using a combination of different polymers. The said formulations having increased viability during processing, storage and upon transfers to the rumen of the dairy animals. Further said formulations having high tolerance to lactate and acetate in the rumen of dairy animals.

The invention relates to a method for the preparation of dry formulations of dairy probiotic bacteria using a combination of different polymers. The said formulations having increased viability during processing, storage and upon transfers to the rumen of the dairy animals. Further said formulations having high tolerance to lactate and acetate in the rumen of dairy animals.

The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.